Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The PRIME Study: Metformin in Patients Initiating Androgen Deprivation Therapy
NCT03031821Phase 3Terminated
- Sponsor
- Canadian Urologic Oncology Group
- Start
- Jul 2018
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liquid metformin (Aspargo Labs) in metabolic syndrome (2 arms), sponsored by Canadian Urologic Oncology Group. Primary endpoint: Proportion of participants who meet the diagnostic criteria for metabolic syndrome at 18 months. Started Jul 2018; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT03031821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031821.